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Background: Immunotherapeutic approaches, such as dendritic cell (DC) vaccination, have emerged as promising
strategies in the treatment of glioblastoma. Despite their promise, however, the absence of objective biomarkers
and/or immunological monitoring techniques to assess the clinical efficacy of immunotherapy still remains a
primary limitation. To address this, we sought to identify a functional biomarker for anti-tumor immune responsiveness
associated with extended survival in glioblastoma patients undergoing DC vaccination.
Methods: 28 patients were enrolled and treated in two different Phase 1 DC vaccination clinical trials at UCLA. To
assess the anti-tumor immune response elicited by therapy, we studied the functional responsiveness of pre- and
post-vaccination peripheral blood lymphocytes (PBLs) to the immunostimulatory cytokines interferon-gamma (IFN-γ)
and interleukin-2 (IL-2) in 21 of these patients for whom we had adequate material. Immune responsiveness was
quantified by measuring downstream phosphorylation events of the transcription factors, STAT-1 and STAT-5, via
phospho-specific flow cytometry.
Results: DC vaccination induced a significant decrease in the half-maximal concentration (EC-50) of IL-2 required to
upregulate pSTAT-5 specifically in CD3+CD8+ T lymphocytes (p < 0.045). Extended survival was also associated with an
increased per cell phosphorylation of STAT-5 in cytotoxic T-cells following IL-2 stimulation when the median post/pre
pSTAT-5 ratio was used to dichotomize the patients (p = 0.0015, log-rank survival; hazard ratio = 0.1834, p = 0.018).
Patients whose survival was longer than two years had a significantly greater pSTAT-5 ratio (p = 0.015), but, contrary to
our expectations, a significantly lower pSTAT-1 ratio (p = 0.038).
Conclusions: Our results suggest that monitoring the pSTAT signaling changes in PBL may provide a functional
immune monitoring measure predictive of clinical efficacy in DC-vaccinated patients.
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Immunotherapy for the treatment of cancer has begun
to show clinical benefit, with several agents recently
gaining FDA approval [1,2]. One such approach being
studied for the treatment of glioblastoma is the adminis-
tration of dendritic cells (DC), loaded with autologous* Correspondence: rprins@mednet.ucla.edu
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unless otherwise stated.tumor lysate or glioma-associated antigens, to engender
an immunologic response against these tumors. Initial
studies of DC-based vaccine therapy for malignant gli-
omas have shown acceptable safety and toxicity profiles,
and multi-center randomized Phase II and III studies are
currently underway [3-18]. As these and other similar
agents transition to clinical use, immunomonitoring as-
says must be developed in order to monitor whether in-
dividual patients are responding to therapy [19], and to
predict who may respond in the future.
In previous clinical trials, the majority of the immune
monitoring strategies employed have not yielded anl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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type hypersentivity (DTH) responses, immunohistochem-
istry, ELISpot and measurement of cytokines produced by
activated lymphocytes in blood and cell culture using
ELISA, have been studied [3-5,10-12,14,20-24], but have
yielded conflicting results. Many of these assays are not
cell type specific, and rather, measure effects in the entire
population of cells, which can dilute the activity of small
populations of highly active cells. Flow cytometry can be
used for the highly sensitive and precise measurement of
cell type frequencies and cytokine release assays. However,
there has not been a consensus set of cell surface pheno-
type profiles or intracellular cytokine staining approach
that is consistent with vaccine-elicited immune and clin-
ical responses [25,26]. To date, no single immune moni-
toring assay has consistently shown a correlation with
immune response to DC vaccination or with overall sur-
vival of patients receiving DC vaccines.
Our understanding of the determinants of effector im-
munity as well as the agents of cancer-induced immune
dysfunction continues to evolve and immune monitoring
efforts should reflect these insights [27,28]. Available evi-
dence suggests that lymphocyte responsiveness to cyto-
kines is a key determinant in the generation and
maintenance of immune effector cells [29,30]. This re-
sponsiveness has been found to be context dependent
and variably impaired in cancer patients [31-36]. While
this may be due to innate, individual patient-specific fac-
tors, it may also result from cancer-induced immune
dysfunction and be reflective of the overall balance of
proinflammatory and immune regulatory factors influen-
cing the internal milieu, and appears especially promin-
ent in patients with malignant glioma [27,28].
Phosphoflow, a flow cytometry-based technique to
measure the phosphorylation status of key intracellular
signaling molecules such as STATs, can be used to
measure, on a per-cell basis, the capability of different
immune cell populations to respond to cytokines [37].
The JAK-STAT signaling pathways lead to the phosphy-
lation of STAT-1 and STAT-5, and are activated by the
binding of cytokines IFN-γ and IL-2, respectively, to
cytokine receptors located on the cell membrane [38].
The phosphorylated STATs (pSTAT) form dimers that
trans-locate into the nucleus to initiate gene transcrip-
tion programs. As a downstream product, the measure-
ment of phosphorylated STATs serves to quantify the
functional capacity of cells to respond to cytokines,
which in turn should reflect whether they remain func-
tional or have reached an anergic or tolerogenic state
where they are unable to respond. Previously, our group
has found evidence suggesting that the surrounding im-
mune environment factors into the success or failure of
DC vaccines with gene expression profiling, regulatory
cell frequency, and the expression of negative regulatorymolecules all associating with vaccine success [9,12,39]. In
the present study, we analyzed the phosphorylation events
of STAT-1 and STAT-5 following cytokine stimulation
with IFN-γ and IL-2, respectively, in order to determine
the functional responsiveness of PBL subpopulations and
compared this responsiveness before and after DC vaccin-
ation. We hypothesized that changes in the functional
cytokine responsiveness of lymphocyte sub-populations,
pre to post DC vaccination, would convey important in-
formation regarding the effectiveness of the vaccine in a
non-antigen-specific manner. Such an approach could be
used as a uniform surrogate for immunotherapy. Herein,
we report that DC vaccination reproducibly enhances IL-2
responsiveness in PBL, and increases in overall survival
were observed in glioblastoma patients whose IL-2 re-
sponsiveness was elevated. Contrary to our expectations,
we also found a negative correlation with responsiveness
to IFN-γ, as measured by pSTAT-1, wherein reduced re-
sponsiveness to IFN- γ- was associated with improved
survival.
Results
DC vaccination results in a reduction of the EC-50 for IL-2
in peripheral blood CD3+CD8+ T cells
We hypothesized that DC vaccination would activate
and expand glioma-specific T cells whose recall response
to gamma chain survival cytokines and/or TH1-type cy-
tokines, such as interleukin 2 (IL-2) and interferon
gamma (IFN-γ), would be enhanced. To test this, differ-
ences in the functional responsiveness of PBMC subsets
following DC vaccination were evaluated and compared
with each patient’s overall survival using a Cox Propor-
tional Hazard model and Kaplan-Meier survival analysis.
In order to assess functional responsiveness, the dy-
namic levels of activated pSTAT-1 and pSTAT-5 within
PBMCs was monitored following a short 20-minute
ex vivo IFN-γ or IL-2 stimulation, respectively. Phospho-
specific flow cytometric analysis of patient PBMCs was
quantified in the following subsets of PBMCs: Mono-
cytes (CD3-CD14+), Helper T-Cells (CD3+CD4+), Cyto-
toxic T-Cells (CD3+CD8+), and B-Cells (CD3-CD20+)
(Figure 1). Inherent heterogeneity in PBMC compositions
and intracellular pSTAT populations between patients was
controlled for by generating post to pre DC vaccination
ratios for every leukocyte population in each patient.
Stimulation of PBMC subsets with IL-2 resulted in a
dose-dependent increase in both the percentage (%)
and median fluorescence intensity (MFI) of pSTAT-5 in
CD3+CD4+ and CD3+CD8+ T lymphocytes (Figure 2A).
Such a dose-dependent relationship was not prevalent
for pSTAT-1 in response to IFN-γ stimulation (data not
shown). We also evaluated whether the half-maximal
effective concentration (EC-50) of IL-2 changed after
DC vaccination, and if changes in the EC-50 of IL-2
Figure 1 Gating schematic for phospho-flow cytometry staining. PBMC (pre/post DC vaccination) were stimulated with either IFN-γ (pSTAT-1;
not shown) or IL-2 (pSTAT-5) for 20 minutes, followed by phospho-flow cytometry. Cells were surface labeled with antibodies to CD3, CD4, CD8, CD14,
and CD20, followed by fixation, permeabilization, and intracellular staining with antibodies to pSTAT-1 and pSTAT-5. In the pSTAT-5 histograms the red
tracing represents unstimulated, while the blue tracing represents IL-2 stimulated cell populations.
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from whom we had sufficient cells for complete dose
response stimulations, a reduction in the EC-50 for IL-
2 was observed in CD3+CD8+ T cells after DC vaccin-
ation, but not in CD3+CD4+ T cells (Figure 2B, Table 1).
We also observed an increase in the percentage of CD3 +CD8+ T cells expressing pSTAT-5, at a given dose of
IL-2 stimulation, after DC vaccination in selected pa-
tients (Figure 2), mirroring findings from our pre-
clinical model [40]. When the ratio of each patient’s
EC-50 for IL-2 (post/pre DC vaccination) was analyzed
using Cox Regression, a significant association with
B)
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Figure 2 Dose-dependent changes in pSTAT-5 by CD3+CD8+ T cells in response to IL-2. PBMC (pre/post DC vaccination) were stimulated
with graded doses of IL-2 for 20 minutes, followed by intracellular staining for pSTAT-5. (A) Representative example of the pSTAT-5 dose response
staining from patient #GAA-03 before (top) and after (bottom) DC vaccination. (B) Non-linear plot comparing the dose response of CD3 + CD8+ T
lymphocytes before and after DC vaccination in patient #GAA-03. The calculated EC-50 values are listed.
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(1.11, 4.43); p = 0.024). These results strongly suggest
that DC vaccination is specifically followed by a height-
ened response to a typical gamma chain cytokine asso-
ciated with lymphocyte survival in cytotoxic T cells
from glioblastoma patients.Table 1 IL-2 responsiveness in peripheral blood T cells before
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dosages of IL-2, FACS analysis, and log transformation.Changes in CD8+ T-Cell responsiveness to IL-2 correlates
with survival after DC vaccination in glioblastoma patients
A Cox proportional hazards model was also utilized to
investigate the correlation between the functional re-
sponsiveness of PBL to a single, fixed dose of cytokine
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peripheral responses of 20/28 glioblastoma patients
treated with DC vaccination. Comparison of MFI fold-
change ratios in CD3-CD14+ Monocytes, CD3+CD4+
Helper T-cells, and CD3-CD20+ B-cell populations
(post/pre DC vaccination) with patient survival yielded
no statistically significant correlations. However, a sta-
tistically significant positive correlation was observed
between the CD3+CD8+pSTAT5+% and MFI (post
DCVax/pre DCVax ratio) after a single dose of IL-2
stimulation and overall patient survival (Figure 3A-B;
hazard ratio = 0.1834; 95% CI = 0.045, 0.749; p = 0.018).
As is apparent in Figure 3, CD3 + CD8+ T cells whose
responsiveness to IL-2 was elevated after DC vaccin-
ation compared with before DC vaccination (Figure 3B)
had signficantly longer overall survival than patients
whose CD3 + CD8+ T cell responsiveness to IL-2 did
not change (Figure 3A). Based on this correlation, a
one unit increase in the ratio of the pSTAT-5 ratio


















Figure 3 T cell responses to STAT-5 are associated with overall surviv
(pre/post DC vaccination) were either left unstimulated or stimulated with
histograms were gated from CD3+CD8+ T cells. Representative histograms
expression in PBL samples when unstimulated, or stimulated with 500 IU IL
pSTAT-5 expression before and after DC vaccination.cytotoxic T-cells following DC vaccination reduces the
risk of death in vaccinated patients by 5.45 times.
A recursive partitioning survival tree was also used to
dichotomize the pSTAT-5 post/pre DC vaccination ratio
in CD8+ T-cells. This model was implemented as a
means to develop a functional immune monitoring
measure of immunological responses predictive of clin-
ical efficacy in DC-vaccinated patients. To stratify pa-
tients in an unbiased fashion, we chose the median
pSTAT-5 ratio (post/pre DC vaccination) as a cut-off,
which effectively segregated patients whose pSTAT-5 ra-
tio increased (>1) or decreased (<1) after treatment.
When the median pSTAT-5 ratio (post/pre DC vaccin-
ation) in CD3+CD8+ T cells was used to dichotomize pa-
tients, a highly significant difference in survival was
observed (p = 0.003, Log-rank test). The median survival
below this cut-off value was 17.25 months (95% C.I.
(11.0, 23.0) and 46.3 months (95% C.I. (22.3, NA)) above
the cut-off value (Figure 4). Therefore, the development
of elevated pSTAT-5 expression in CD3+CD8+ T cellstient #34-730
TAT5 post/pre 
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Figure 4 Predictive immune monitoring using pSTAT-5 expression in peripheral blood lymphocytes from glioblastoma patients treated
with DC vaccination. A recursive partitioning survival tree was calculated from the median pSTAT-5 ratio in CD3+CD8+ T lymphocytes to
dichotomize patient subsets. Kaplan-Meier survival is plotted.
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tended survival in glioblastoma patients.
Reciprocal pSTAT responsiveness in CD8+ T lymphocytes
after DC vaccination correlates with survival in
glioblastoma patients
2-year survival is known to be a significant endpoint for
glioblastoma patients who receive standard-of-care treat-
ment [41-44]. Based on our analysis of pSTAT-1 and
pSTAT-5 expression in PBL before, and after DC vaccin-
ation, we stratified glioblastoma patients based on 2-year
survival. We then examined the phosporylation of
STAT-1 and STAT-5 from CD3+CD8+ T cells. A signifi-
cant difference was found between the ratio (post/pre
vaccination) of pSTAT-1 and pSTAT-5 when stratifed by
2-year survival (Figure 5). Patients with overall survival
greater than 2 years had a significantly greater pSTAT-5
ratio (p = 0.015), but significantly lower pSTAT-1 ratio
(p < 0.038). Therefore, reciprocal responses to IL-2 and
IFN-γ after DC vaccination are also associated with one
of the primary survival endpoints in glioblastoma.
Discussion
Our findings provide evidence that alterations in cyto-
kine responsiveness of PBLs from glioblastoma patients
treated with dendritic cell vaccination are associated
with overall survival and may be reflective of vaccine ef-
ficacy. We measured STAT phosphorylation in the PBLsof glioblastoma patients enrolled in clinical trials of au-
tologous tumor lysate loaded or tumor antigen associated
peptide pulsed dendritic cell vaccine. Initial measurements
were taken from PBLs before the patient had received the
DC vaccine. Comparison measurements were made on
PBL from patients after three biweekly DC vaccinations
were given. When ratios of cytokine responsiveness were
compared in an individual pre- and post-vaccination, we
found a strong correlation that enhanced responsiveness
of CD8+ T lymphocytes to IL-2 was associated with long-
term survival of greater than 2 years. DC vaccination
reproducibly induced elevated IL-2 (pSTAT-5) responsive-
ness, the magnitude of which was also directly associated
with survival. An increased responsiveness to IFN-γ
(pSTAT-1) at the 6-week post-vaccine time point com-
pared to pre-vaccination, on the other hand, was unex-
pectedly associated with worsened prognosis. We believe
such information, if validated, could be used to help deter-
mine if a patient was successfully responding to immuno-
therapy with DC vaccination.
This phospho-flow immune monitoring study is the
first, to our knowledge, to assess the effectiveness of a
clinical immunotherapy trial in glioblastoma patients
using a functional technique not based on antigen-
specific T responses. These studies stem directly from
pre-clinical results in which pro-inflammatory cytokine
production was shown to enhance the expansion and
survival of glioma-specific CD8+ T cells after DC














































Figure 5 pSTAT-5 and pSTAT-1 expression in CD3+CD8+ T cells effectively segregates glioblastoma patients after DC vaccination. The
post-Tx/pre-Tx ratio of stimulated pSTAT-5 (A) or pSTAT-1 (B) MFI were compared with patients whose overall survival was less than or greater
than 2 years. *p = 0.015 for pSTAT-5, *p = 0.0382 for pSTAT-1 (2-tailed T-test).
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yet, it is unclear exactly which subset of CD4+ or CD8+
T lymphocytes may be directly influenced by DC vaccin-
ation. Our pre-clinical studies suggest that local pro-
inflammatory cytokine production after DC vaccination
enhanced the generation of effector memory CD8+ T
lymphocyte populations (CD44hi, Eomeslow, CCR7low),
but with evidence of a lymph node homing phenotype
and central memory cell markers (CD62L+, CD49d+)
[40]. Our clinical immune monitoring design did not
allow us to additionally determine whether distinct T
lymphocyte subsets were sensitized to STAT-5 signaling,
but we are currently designing new antibody cocktails
that will allow for such simultaneous data acquisition
(CD45RO, CD62L, CCR7) in our ongoing clinical trials.
We believe that such an immune monitoring tool is
critical for a vaccine comprised of DC pulsed with
autologous tumor lysate because each patient’s array of
tumor-associated antigens will be distinct, and thus the
identity of each patient’s tumor-specific T cells will
additionally be different. We also believe that such an
immune monitoring strategy will also be important in
the future because meta-analyses have demonstrated
that vaccination with whole-tumor antigens induced
higher objective clinical responses than vaccination with
defined tumor antigens [46]. The recent clinical success
of negative costimulatory molecule blockade in patients
of diverse solid tumor histology [47,48] suggests that
immune monitoring of non-antigen-specific lymphocyte
function could also disclose relevant information on the
endogenous anti-tumor immune response.
In addition to being a surrogate marker that may indi-
cate a successful DC vaccination, the levels of cytokine
responsiveness before and after vaccination may shed
insight into the cellular mechanisms that are important
for a generating an effective long-term immune re-
sponse. Active immunotherapies, such as dendritic cell
vaccines, depend on provoking a host immune response,the ultimate goal of which is the generation of potent,
long-lasting tumor-specific T lymphocytes. Such T cells
are thought to develop against many tumors, but are ul-
timately defeated by the immunosuppressive effects of
the tumors themselves, which secrete anti-inflammatory
cytokines both systemically and into the tumor micro-
environment and activate immune-regulatory cell popu-
lations. The major signaling pathway induced by IL-2 is
through phosphorylation of STAT-5. When the post:pre
ratio of pSTAT-5 was examined, it was clear that pa-
tients who demonstrated improved survival had ratios
greater than 1 and developed a reduced EC-50 to IL-2.
Our hypothesis is that immune suppression from the
brain tumor acts as an antagonist to IL-2 signaling in T
cells, which is counteracted by the DC vaccine. Biologic-
ally, this suggests that the CD8+ lymphocytes either be-
came more responsive to IL-2 (e.g., increased potency)
or expressed elevated levels of pSTAT-5 after vaccin-
ation. We have previously shown that enhanced sensitiv-
ity to IL-2 signaling and frequency of pSTAT-5 regulates
the clinical responsiveness of IL12-primed CD8+ T cells
to intracranial tumors [40]. STAT-5 signaling also plays
a crucial role in normal immune function. STAT-5 is re-
quired for IL-2-induced cell cycle progression in T cells
and is required for antigen-induced T-cell recruitment
into tumor tissue [49]. Mice deficient in STAT5 exhibit
alterations in NK cell function and decreased T-cell and
B-cell proliferation in response to chemokines [50].
Thus, increased pSTAT-5 responsiveness to IL-2 may
suggest that the DC vaccine has overcome the immuno-
suppressive effects of the tumor and effectively primed
glioma-specific T cells.
The major signaling pathway induced by IFN-γ is
through the phosphorylation of STAT-1. IFN-γ is a well-
characterized molecule and plays a central role in the
immune response. Many assays assessing cellular im-
mune function do so by measuring the release of IFN-γ
in response to a stimulus, such as antigen recognition by
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tion of elevated pSTAT-1 expression would be beneficial.
However, we observed the opposite to be true; in pa-
tients that demonstrated an increased post:pre pSTAT1
ratio, overall survival tended to be worse. There are sev-
eral possible explanations for this, which mostly center
on the chronicity of the IFN-γ signaling. Recent studies
indicate that IFN-γ has pleiotropic effects on the im-
mune system, with different effects during primary and
secondary responses to an antigen [51]. At first stimula-
tory, over time, continued exposure to IFN-γ can lead to
feedback inhibition in order to limit excessive tissue de-
struction and autoimmune disease. The main mecha-
nisms behind these immunoregulatory roles of IFN-γ
have included its ability to promote activation and func-
tion of regulatory T cells through DC-mediated immuno-
suppression via induction of tryptophan catabolizing
enzyme IDO, iNOS, and HO-1 [52]. Therefore, increased
IFN-γ signaling after DC vaccination may actually indicate
that immune responses initially created by the DC vaccin-
ation are being actively suppressed/tolerized when mea-
sured 6 weeks later.
Conclusions
A statistically significant relationship was found between
the levels of cytokine responsiveness, pre and post vac-
cination, and overall survival in glioblastoma patients on
clinical trials of DC immunotherapy. These data suggest
that increased ratios of IL-2 responsiveness/pSTAT5 sig-
naling and decreased ratios of IFN-γ responsiveness/
pSTAT1 signaling may be associated with better progno-
sis in this patient population. We believe that cytokine
responsiveness may be a novel immune monitoring
measure to evaluate the effectiveness of the anti-tumor
immune response in a non-antigen-specific fashion.
Such a technique could be utilized to assess the function
of a number of peripheral blood leukocyte populations




Twenty-eight patients with histologically diagnosed glio-
blastoma (WHO Grade IV) were enrolled into one of two
Phase 1 clinical trials at UCLA investigating the use of au-
tologous tumor lysate (ATL; UCLA IRB #03-04-053, FDA
IND #11053, clinical trial registration #NCT00068510;
n = 23)) or glioma-associated antigen (GAA)-pulsed
(UCLA IRB #06-01-052, FDA IND #12966, clinical trial
registration #NCT00612001; n = 5) DC vaccination.
This study examined the 21 of 28 eligible patients for
which there was adequate patient material. Of these evalu-
able patients, 17 patients underwent ATL pulsed DC im-
munotherapy, while four underwent GAA peptide-pulsedDC immunotherapy between 2003 and 2010. The demo-
graphics of patients receiving either treatment modality
included 15 males and 5 females, ranging from 26-70 years
old. The clinical characteristics of these patients, with
multi-variate clinical comparisons, have been published
previously [18]. Patient inclusion/exclusion criteria for
these studies can be found at ClinicalTrials.gov (http://
clinicaltrials.gov/). All patients received three biweekly
vaccinations with autologous DC after surgical resection
for tumor removal. All PBL used in these analyses were
isolated from patients at day 0, prior to the first DC vac-
cination, and at day 42, two weeks after the third DC vac-
cination. During the six weeks of this DC vaccination
treatment course, and as a requisite for trial eligibility, all
patients were free of any concomitant medications known
to affect immune cell function (e.g., chemotherapy, corti-
costeroids). All patients provided written informed con-
sent according to UCLA Medical Internal Review Board
(IRB) guidelines before treatment. Informed consent was
approved by the UCLA Medical IRB and given by patients
for their experimental treatment, storage of clinical data
in a secured database, and research performed on residual
patient tissues.
Collection and storage of PBMC for immune monitoring
PBMCs were obtained from the peripheral blood of pa-
tient subjects in compliance with UCLA Medical IRB
protocols. Peripheral blood was drawn from patients at
various time points both pre and post DC vaccination.
PBMCs from the peripheral blood were collected via
Ficoll extraction and subsequently placed in a freezing
media of 10% DMSO and 90% serum for storage in li-
quid nitrogen.
Cytokine stimulation of normal PBMC and patient PBMC
Normal PBMC and patient PBMC (pre and post DC vac-
cination) samples were thawed at 37°C, resuspended in X-
Vivo culture media and rested overnight. Following the
overnight rest, cells were enumerated and resuspended in
a volume of X-Vivo with 0.1% B-mercaptoethanol and 2%
FBS to obtain 1x106 cells/mL. Cells were then stimulated
with IL-2 or IFN-γ. Each aliquot received a different treat-
ment of cytokine, either IFN-γ, IL-2, or no stimulation.
IFN-γ stimulated aliquots received 0.1 ng, 1 ng, 10 ng, or
100 ng IFN-γ. IL-2 stimulated aliquots received 100 U,
500 U, 1000 U, or 5000 U IL2. Once the cytokines had
been added, the cells were incubated at 37°C for
20 minutes.
Intracellular antibody staining
Following cytokine stimulation, the cells were fixed with
100 uL of 16% paraformaldehyde for a final concentration
of 1.6% paraformaldehyde and incubated for 10 minutes
at room temperature. After incubation, the cells were then
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107 cells/mL in staining media, and transferred to new
tubes and stained accordingly. Among the 10 normal
PBMC samples were seven single colored controls in-
cluding CD3 FITC, CD14 Pacific Blue, CD4 Alexa Fluor
647, CD3 APC-Cy7, CD4 PE, CD20 PC-5.5, and CD8
PE-Cy7. The three additional normal PBMC samples
were used to create normal stained and unstained cyto-
kine unstimulated controls and a “color -2” control
(containing all single color control stains excluding the
FITC and AF647-conjugated antibodies). For the remaining
patient PBMC samples, an antibody cocktail was cre-
ated in order to ensure consistent staining of patient
PBMCs. The antibody cocktail was composed of
pSTAT-1 FITC, pSTAT-5 AF647, CD3 APC-Cy7, CD4
PE-Cy7, CD8 PB, CD14 PE, and CD20 PerCP-Cy5.5.
The samples were subsequently incubated for 30 mi-
nutes at room temperature away from light.
Flow cytometric analysis
Experimental data was collected via multi-color flow cy-
tometry of the stained PBMCs using the BD LSRII flow
cytometer and BD FACS diva software. In calibrating the
flow cytometer, only the seven colors of interest were se-
lected. The negative control was then analyzed and FSC
and SSC voltages were modified in order to optimize the
visibility of the lymphocyte population. Once properly
gated, the single colored compensation controls were ac-
quired and the voltages were modified in order to place
the peak of the stained cells at 104. Each single color
control was gated in relative to the negative unstained
control and all compensation controls were applied.
Afterwards, each experimental sample was acquired at
200,000 events per sample.
Statistical analysis
The raw data was aggregated and tabulated for analysis
and study using GraphPad software v5.03 (GraphPad
Software, La Jolla, CA). Descriptive statistics such as
mean and standard deviation were used to summarize
continuous variables, while count and percentage were
used for categorical variables. Bivariate comparisons of
continuous variables and categorical variables were per-
formed using unpaired t-tests. The Kaplan Meier
method and log-rank test were used to summarize the
overall survival and time to progression of both trials.
Univariate and multivariate Cox proportional hazards re-
gression models were used to correlate the individual
immune monitoring variables with overall survival. Re-
cursive partitioning survival trees were built to obtain
the cut-off values utilized to dichotomize each immune
monitoring variable, which could differentiate the overall
survival between the variables. EC-50 curves for IL-2
were generated in a standard fashion using 4-5 logdilutions of stimulatory cytokines. The log of the dose
vs. response were found to follow a symmetrical sig-
moidal shape and plotted using GraphPad Prism. The
EC-50 was calculated using the equation: Y = bottom +
(top-bottom)/(1 + 10^(log EC50-x)). The calculated EC-
50 is the concentration of dose (IL-2) that elicits a
response halfway between bottom and top. For all statis-
tical investigations, tests for significance were two tailed,
with a statistically significant p-value threshold of 0.05.
Statistical analyses were performed using SAS 9.2 (SAS
institute, Cary, NC).
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